Castle Biosciences, Inc. (NASDAQ:CSTL) Receives $40.29 Consensus Target Price from Brokerages
Shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) have been given a consensus rating of “Buy” by the seven ...
Principal Financial Group Inc. Has $38.26 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)
Principal Financial Group Inc. decreased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) by 6.7% in the fourth quarter, according to the company in its most recent ...
Medscape26d
Barrett's Esophagus: Can Biomarkers Predict Progression to Malignancy?
Similar to the adenoma-carcinoma sequence of colorectal carcinomas, esophageal adenocarcinoma develops through progression from BE to low- and high-grade dysplasia, then to adenocarcinoma with ...
Medscape6d
Barrett's Esophagus: Clinical Implications
Esophageal resection is the standard of care in patients with confirmed high-grade dysplasia. In patients with comorbid conditions, endoscopic ablation methods and long-term endoscopic ...
ascopubs.org27d
Optical coherence tomography and elastography for the visualization of architecture and stiffness differences in gastric cancer and dysplasia.
Effect of adjuvant radiotherapy after endoscopic resection of early esophagus cancer to prevent new intraluminal mucosal recurrence. This is an ASCO Meeting Abstract from the 2025 ASCO ...
SciELO19d
Digestive tract toxicity associated with exposure to 2,4-dichlorophenoxyacetic acid in rats
In the present study, we observed esophageal hyperkeratosis in most animals exposed to 2,4-D (regardless of route or concentration). Animals exposed to moderate and high concentrations of 2,4-D ...
Frontiers20d
Case report: Watch-and-wait strategy in resectable esophageal cancer following neoadjuvant chemoimmunotherapy: a case series
In cases where the initial biopsy revealed indeterminate lesions (e.g., dysplasia or precancerous lesions), during ... NCRT followed by surgery is the recommended treatment for locally advanced ...
gut.bmj25d
Low-coverage whole genome sequencing of low-grade dysplasia strongly predicts advanced neoplasia risk in ulcerative colitis
Background The risk of developing advanced neoplasia (AN; colorectal cancer and/or high-grade dysplasia) in ulcerative colitis (UC) patients with a low-grade dysplasia (LGD) lesion is variable and ...